Article info
Original research
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
- Correspondence to Dr Robert L Coleman, The US Oncology Network, The Woodlands, TX 77380, USA; rcoleman{at}gog.org
Citation
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
Publication history
- Received July 16, 2020
- Revision received August 17, 2020
- Accepted August 25, 2020
- First published October 9, 2020.
Online issue publication
November 02, 2020
Article Versions
- Previous version (9 October 2020).
- Previous version (21 October 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.